nodes	percent_of_prediction	percent_of_DWPC	metapath
Methyclothiazide—CA2—kidney cancer	0.671	1	CbGaD
Methyclothiazide—SLC12A3—collecting duct of renal tubule—kidney cancer	0.0329	0.239	CbGeAlD
Methyclothiazide—SLC12A1—collecting duct of renal tubule—kidney cancer	0.0251	0.182	CbGeAlD
Methyclothiazide—SLC12A3—nephron—kidney cancer	0.0146	0.106	CbGeAlD
Methyclothiazide—CA2—collecting duct of renal tubule—kidney cancer	0.0112	0.0813	CbGeAlD
Methyclothiazide—SLC12A1—nephron—kidney cancer	0.0112	0.0811	CbGeAlD
Methyclothiazide—SLC12A1—urine—kidney cancer	0.00896	0.065	CbGeAlD
Methyclothiazide—CA4—Erythrocytes take up carbon dioxide and release oxygen—CA2—kidney cancer	0.00658	0.131	CbGpPWpGaD
Methyclothiazide—CA1—Erythrocytes take up carbon dioxide and release oxygen—CA2—kidney cancer	0.00604	0.12	CbGpPWpGaD
Methyclothiazide—CA4—Reversible hydration of carbon dioxide—CA2—kidney cancer	0.00522	0.104	CbGpPWpGaD
Methyclothiazide—CA1—Reversible hydration of carbon dioxide—CA2—kidney cancer	0.0048	0.0954	CbGpPWpGaD
Methyclothiazide—CA4—Reversible hydration of carbon dioxide—CA9—kidney cancer	0.00396	0.0787	CbGpPWpGaD
Methyclothiazide—CA2—Reversible hydration of carbon dioxide—CA9—kidney cancer	0.0038	0.0754	CbGpPWpGaD
Methyclothiazide—CA1—Reversible hydration of carbon dioxide—CA9—kidney cancer	0.00364	0.0723	CbGpPWpGaD
Methyclothiazide—SLC12A3—nephron tubule—kidney cancer	0.00316	0.0229	CbGeAlD
Methyclothiazide—SLC12A3—renal system—kidney cancer	0.00287	0.0208	CbGeAlD
Methyclothiazide—SLC12A3—kidney—kidney cancer	0.00278	0.0202	CbGeAlD
Methyclothiazide—SLC12A3—cortex of kidney—kidney cancer	0.0027	0.0196	CbGeAlD
Methyclothiazide—SLC12A1—nephron tubule—kidney cancer	0.00241	0.0175	CbGeAlD
Methyclothiazide—SLC12A1—renal system—kidney cancer	0.00219	0.0159	CbGeAlD
Methyclothiazide—SLC12A1—kidney—kidney cancer	0.00212	0.0154	CbGeAlD
Methyclothiazide—SLC12A1—cortex of kidney—kidney cancer	0.00206	0.015	CbGeAlD
Methyclothiazide—CA1—renal system—kidney cancer	0.00151	0.011	CbGeAlD
Methyclothiazide—CA1—kidney—kidney cancer	0.00146	0.0106	CbGeAlD
Methyclothiazide—CA4—nephron tubule—kidney cancer	0.0013	0.00942	CbGeAlD
Methyclothiazide—CA4—renal system—kidney cancer	0.00118	0.00856	CbGeAlD
Methyclothiazide—CA4—kidney—kidney cancer	0.00114	0.00827	CbGeAlD
Methyclothiazide—CA4—cortex of kidney—kidney cancer	0.00111	0.00806	CbGeAlD
Methyclothiazide—CA2—nephron tubule—kidney cancer	0.00108	0.00781	CbGeAlD
Methyclothiazide—CA4—cardiac atrium—kidney cancer	0.00106	0.00767	CbGeAlD
Methyclothiazide—CA2—renal system—kidney cancer	0.000978	0.0071	CbGeAlD
Methyclothiazide—CA2—kidney—kidney cancer	0.000946	0.00686	CbGeAlD
Methyclothiazide—CA2—cortex of kidney—kidney cancer	0.000921	0.00668	CbGeAlD
Methyclothiazide—CA2—cardiac atrium—kidney cancer	0.000876	0.00636	CbGeAlD
Methyclothiazide—Hydroflumethiazide—KCNMA1—kidney cancer	0.000836	0.0937	CrCbGaD
Methyclothiazide—Hydrochlorothiazide—KCNMA1—kidney cancer	0.000814	0.0911	CrCbGaD
Methyclothiazide—CA1—C-MYB transcription factor network—CD34—kidney cancer	0.000684	0.0136	CbGpPWpGaD
Methyclothiazide—Metolazone—CA9—kidney cancer	0.000662	0.0741	CrCbGaD
Methyclothiazide—SLC12A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC5A5—kidney cancer	0.000599	0.0119	CbGpPWpGaD
Methyclothiazide—Benzthiazide—CA9—kidney cancer	0.000598	0.067	CrCbGaD
Methyclothiazide—Diclofenamide—CA9—kidney cancer	0.000594	0.0665	CrCbGaD
Methyclothiazide—Quinethazone—CA2—kidney cancer	0.000579	0.0648	CrCbGaD
Methyclothiazide—SLC12A3—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC5A5—kidney cancer	0.000544	0.0108	CbGpPWpGaD
Methyclothiazide—Cyclothiazide—CA2—kidney cancer	0.000538	0.0602	CrCbGaD
Methyclothiazide—Benzthiazide—CA2—kidney cancer	0.000538	0.0602	CrCbGaD
Methyclothiazide—Chlorothiazide—CA2—kidney cancer	0.000534	0.0598	CrCbGaD
Methyclothiazide—Diclofenamide—CA2—kidney cancer	0.000534	0.0598	CrCbGaD
Methyclothiazide—SLC12A1—SLC-mediated transmembrane transport—SLC5A3—kidney cancer	0.000507	0.0101	CbGpPWpGaD
Methyclothiazide—Hydroflumethiazide—CA9—kidney cancer	0.000501	0.0561	CrCbGaD
Methyclothiazide—Hydrochlorothiazide—CA9—kidney cancer	0.000488	0.0546	CrCbGaD
Methyclothiazide—Photosensitivity—Capecitabine—kidney cancer	0.000477	0.00361	CcSEcCtD
Methyclothiazide—Malnutrition—Sorafenib—kidney cancer	0.000476	0.0036	CcSEcCtD
Methyclothiazide—Hyperglycaemia—Gemcitabine—kidney cancer	0.000476	0.0036	CcSEcCtD
Methyclothiazide—Body temperature increased—Temsirolimus—kidney cancer	0.000475	0.0036	CcSEcCtD
Methyclothiazide—Pneumonia—Gemcitabine—kidney cancer	0.000473	0.00358	CcSEcCtD
Methyclothiazide—Erythema multiforme—Dactinomycin—kidney cancer	0.000471	0.00356	CcSEcCtD
Methyclothiazide—Vascular purpura—Capecitabine—kidney cancer	0.000469	0.00355	CcSEcCtD
Methyclothiazide—Orthostatic hypotension—Paclitaxel—kidney cancer	0.000467	0.00353	CcSEcCtD
Methyclothiazide—Stevens-Johnson syndrome—Gemcitabine—kidney cancer	0.000466	0.00353	CcSEcCtD
Methyclothiazide—Haemolytic anaemia—Capecitabine—kidney cancer	0.000464	0.00351	CcSEcCtD
Methyclothiazide—SLC12A3—SLC-mediated transmembrane transport—SLC5A3—kidney cancer	0.000461	0.00916	CbGpPWpGaD
Methyclothiazide—Cramp muscle—Paclitaxel—kidney cancer	0.00046	0.00348	CcSEcCtD
Methyclothiazide—Glycosuria—Doxorubicin—kidney cancer	0.000459	0.00348	CcSEcCtD
Methyclothiazide—Malnutrition—Sunitinib—kidney cancer	0.000458	0.00347	CcSEcCtD
Methyclothiazide—Muscle spasms—Sorafenib—kidney cancer	0.000457	0.00346	CcSEcCtD
Methyclothiazide—Hydroflumethiazide—CA2—kidney cancer	0.000451	0.0505	CrCbGaD
Methyclothiazide—SLC12A1—Transmembrane transport of small molecules—RYR1—kidney cancer	0.000449	0.00892	CbGpPWpGaD
Methyclothiazide—Hypersensitivity—Temsirolimus—kidney cancer	0.000443	0.00335	CcSEcCtD
Methyclothiazide—Muscle spasms—Sunitinib—kidney cancer	0.00044	0.00333	CcSEcCtD
Methyclothiazide—Thrombocytopenia—Vinblastine—kidney cancer	0.00044	0.00333	CcSEcCtD
Methyclothiazide—Agranulocytosis—Gemcitabine—kidney cancer	0.000439	0.00332	CcSEcCtD
Methyclothiazide—Hydrochlorothiazide—CA2—kidney cancer	0.000439	0.0491	CrCbGaD
Methyclothiazide—Thrombocytopenia—Everolimus—kidney cancer	0.000438	0.00332	CcSEcCtD
Methyclothiazide—Purpura—Capecitabine—kidney cancer	0.000435	0.00329	CcSEcCtD
Methyclothiazide—Trichlormethiazide—CA9—kidney cancer	0.000435	0.0487	CrCbGaD
Methyclothiazide—Pancreatitis—Paclitaxel—kidney cancer	0.000433	0.00328	CcSEcCtD
Methyclothiazide—Asthenia—Temsirolimus—kidney cancer	0.000432	0.00327	CcSEcCtD
Methyclothiazide—Anorexia—Vinblastine—kidney cancer	0.000428	0.00324	CcSEcCtD
Methyclothiazide—Anorexia—Everolimus—kidney cancer	0.000426	0.00323	CcSEcCtD
Methyclothiazide—Leukopenia—Sorafenib—kidney cancer	0.000426	0.00322	CcSEcCtD
Methyclothiazide—Thrombocytopenia—Erlotinib—kidney cancer	0.000423	0.0032	CcSEcCtD
Methyclothiazide—Diarrhoea—Temsirolimus—kidney cancer	0.000412	0.00311	CcSEcCtD
Methyclothiazide—Anorexia—Erlotinib—kidney cancer	0.000411	0.00311	CcSEcCtD
Methyclothiazide—Leukopenia—Sunitinib—kidney cancer	0.00041	0.0031	CcSEcCtD
Methyclothiazide—SLC12A3—Transmembrane transport of small molecules—RYR1—kidney cancer	0.000408	0.0081	CbGpPWpGaD
Methyclothiazide—Asthenia—Pazopanib—kidney cancer	0.000407	0.00308	CcSEcCtD
Methyclothiazide—Paraesthesia—Vinblastine—kidney cancer	0.000403	0.00305	CcSEcCtD
Methyclothiazide—Photosensitivity reaction—Paclitaxel—kidney cancer	0.000403	0.00305	CcSEcCtD
Methyclothiazide—Paraesthesia—Everolimus—kidney cancer	0.000402	0.00304	CcSEcCtD
Methyclothiazide—Hyperuricaemia—Doxorubicin—kidney cancer	0.000401	0.00304	CcSEcCtD
Methyclothiazide—Erythema multiforme—Gemcitabine—kidney cancer	0.000399	0.00302	CcSEcCtD
Methyclothiazide—Hyperglycaemia—Paclitaxel—kidney cancer	0.000398	0.00301	CcSEcCtD
Methyclothiazide—Dizziness—Temsirolimus—kidney cancer	0.000398	0.00301	CcSEcCtD
Methyclothiazide—Pneumonia—Paclitaxel—kidney cancer	0.000396	0.003	CcSEcCtD
Methyclothiazide—Trichlormethiazide—CA2—kidney cancer	0.000391	0.0438	CrCbGaD
Methyclothiazide—Decreased appetite—Vinblastine—kidney cancer	0.00039	0.00295	CcSEcCtD
Methyclothiazide—Stevens-Johnson syndrome—Paclitaxel—kidney cancer	0.00039	0.00295	CcSEcCtD
Methyclothiazide—Decreased appetite—Everolimus—kidney cancer	0.000389	0.00294	CcSEcCtD
Methyclothiazide—Anaphylactic shock—Sorafenib—kidney cancer	0.000388	0.00294	CcSEcCtD
Methyclothiazide—Leukopenia—Dactinomycin—kidney cancer	0.000388	0.00294	CcSEcCtD
Methyclothiazide—Diarrhoea—Pazopanib—kidney cancer	0.000388	0.00293	CcSEcCtD
Methyclothiazide—Constipation—Vinblastine—kidney cancer	0.000384	0.00291	CcSEcCtD
Methyclothiazide—Orthostatic hypotension—Capecitabine—kidney cancer	0.000383	0.0029	CcSEcCtD
Methyclothiazide—Constipation—Everolimus—kidney cancer	0.000383	0.0029	CcSEcCtD
Methyclothiazide—Vomiting—Temsirolimus—kidney cancer	0.000382	0.00289	CcSEcCtD
Methyclothiazide—Thrombocytopenia—Sorafenib—kidney cancer	0.00038	0.00288	CcSEcCtD
Methyclothiazide—Rash—Temsirolimus—kidney cancer	0.000379	0.00287	CcSEcCtD
Methyclothiazide—Blood uric acid increased—Doxorubicin—kidney cancer	0.000379	0.00287	CcSEcCtD
Methyclothiazide—Dermatitis—Temsirolimus—kidney cancer	0.000379	0.00287	CcSEcCtD
Methyclothiazide—Headache—Temsirolimus—kidney cancer	0.000377	0.00285	CcSEcCtD
Methyclothiazide—Decreased appetite—Erlotinib—kidney cancer	0.000375	0.00284	CcSEcCtD
Methyclothiazide—Dizziness—Pazopanib—kidney cancer	0.000375	0.00284	CcSEcCtD
Methyclothiazide—Anorexia—Sorafenib—kidney cancer	0.00037	0.0028	CcSEcCtD
Methyclothiazide—Constipation—Erlotinib—kidney cancer	0.000369	0.00279	CcSEcCtD
Methyclothiazide—Thrombocytopenia—Sunitinib—kidney cancer	0.000366	0.00277	CcSEcCtD
Methyclothiazide—Vomiting—Pazopanib—kidney cancer	0.00036	0.00273	CcSEcCtD
Methyclothiazide—Rash—Pazopanib—kidney cancer	0.000357	0.0027	CcSEcCtD
Methyclothiazide—Nausea—Temsirolimus—kidney cancer	0.000357	0.0027	CcSEcCtD
Methyclothiazide—Dermatitis—Pazopanib—kidney cancer	0.000357	0.0027	CcSEcCtD
Methyclothiazide—Anorexia—Sunitinib—kidney cancer	0.000356	0.0027	CcSEcCtD
Methyclothiazide—Agitation—Vincristine—kidney cancer	0.000356	0.00269	CcSEcCtD
Methyclothiazide—Headache—Pazopanib—kidney cancer	0.000355	0.00269	CcSEcCtD
Methyclothiazide—Body temperature increased—Everolimus—kidney cancer	0.000354	0.00268	CcSEcCtD
Methyclothiazide—CA1—C-MYB transcription factor network—GSTM1—kidney cancer	0.000352	0.007	CbGpPWpGaD
Methyclothiazide—Aplastic anaemia—Doxorubicin—kidney cancer	0.000349	0.00264	CcSEcCtD
Methyclothiazide—Vertigo—Vincristine—kidney cancer	0.000348	0.00263	CcSEcCtD
Methyclothiazide—Leukopenia—Vincristine—kidney cancer	0.000347	0.00262	CcSEcCtD
Methyclothiazide—Thrombocytopenia—Dactinomycin—kidney cancer	0.000346	0.00262	CcSEcCtD
Methyclothiazide—Body temperature increased—Erlotinib—kidney cancer	0.000341	0.00258	CcSEcCtD
Methyclothiazide—Decreased appetite—Sorafenib—kidney cancer	0.000338	0.00255	CcSEcCtD
Methyclothiazide—Anorexia—Dactinomycin—kidney cancer	0.000337	0.00255	CcSEcCtD
Methyclothiazide—Nausea—Pazopanib—kidney cancer	0.000337	0.00255	CcSEcCtD
Methyclothiazide—Paraesthesia—Sunitinib—kidney cancer	0.000336	0.00254	CcSEcCtD
Methyclothiazide—Erythema multiforme—Paclitaxel—kidney cancer	0.000334	0.00253	CcSEcCtD
Methyclothiazide—Constipation—Sorafenib—kidney cancer	0.000332	0.00251	CcSEcCtD
Methyclothiazide—Pulmonary oedema—Doxorubicin—kidney cancer	0.000331	0.00251	CcSEcCtD
Methyclothiazide—Hypersensitivity—Vinblastine—kidney cancer	0.000331	0.0025	CcSEcCtD
Methyclothiazide—Photosensitivity reaction—Capecitabine—kidney cancer	0.000331	0.0025	CcSEcCtD
Methyclothiazide—Hypersensitivity—Everolimus—kidney cancer	0.00033	0.00249	CcSEcCtD
Methyclothiazide—Leukopenia—Gemcitabine—kidney cancer	0.000329	0.00249	CcSEcCtD
Methyclothiazide—Hyperglycaemia—Capecitabine—kidney cancer	0.000327	0.00247	CcSEcCtD
Methyclothiazide—Pneumonia—Capecitabine—kidney cancer	0.000325	0.00246	CcSEcCtD
Methyclothiazide—Decreased appetite—Sunitinib—kidney cancer	0.000325	0.00246	CcSEcCtD
Methyclothiazide—Asthenia—Vinblastine—kidney cancer	0.000322	0.00244	CcSEcCtD
Methyclothiazide—Asthenia—Everolimus—kidney cancer	0.000321	0.00243	CcSEcCtD
Methyclothiazide—Stevens-Johnson syndrome—Capecitabine—kidney cancer	0.00032	0.00242	CcSEcCtD
Methyclothiazide—Constipation—Sunitinib—kidney cancer	0.00032	0.00242	CcSEcCtD
Methyclothiazide—Anaphylactic shock—Vincristine—kidney cancer	0.000316	0.00239	CcSEcCtD
Methyclothiazide—Jaundice—Capecitabine—kidney cancer	0.000315	0.00238	CcSEcCtD
Methyclothiazide—Asthenia—Erlotinib—kidney cancer	0.00031	0.00234	CcSEcCtD
Methyclothiazide—Thrombocytopenia—Vincristine—kidney cancer	0.000309	0.00234	CcSEcCtD
Methyclothiazide—Urticaria—Sorafenib—kidney cancer	0.000309	0.00233	CcSEcCtD
Methyclothiazide—Photosensitivity—Doxorubicin—kidney cancer	0.000308	0.00233	CcSEcCtD
Methyclothiazide—Malnutrition—Paclitaxel—kidney cancer	0.000308	0.00233	CcSEcCtD
Methyclothiazide—Decreased appetite—Dactinomycin—kidney cancer	0.000308	0.00233	CcSEcCtD
Methyclothiazide—Diarrhoea—Vinblastine—kidney cancer	0.000307	0.00233	CcSEcCtD
Methyclothiazide—Body temperature increased—Sorafenib—kidney cancer	0.000307	0.00232	CcSEcCtD
Methyclothiazide—Diarrhoea—Everolimus—kidney cancer	0.000306	0.00232	CcSEcCtD
Methyclothiazide—Vascular purpura—Doxorubicin—kidney cancer	0.000302	0.00229	CcSEcCtD
Methyclothiazide—Agranulocytosis—Capecitabine—kidney cancer	0.000301	0.00228	CcSEcCtD
Methyclothiazide—Anorexia—Vincristine—kidney cancer	0.000301	0.00228	CcSEcCtD
Methyclothiazide—Anaphylactic shock—Gemcitabine—kidney cancer	0.0003	0.00227	CcSEcCtD
Methyclothiazide—Dizziness—Vinblastine—kidney cancer	0.000297	0.00225	CcSEcCtD
Methyclothiazide—Dizziness—Everolimus—kidney cancer	0.000296	0.00224	CcSEcCtD
Methyclothiazide—Muscle spasms—Paclitaxel—kidney cancer	0.000296	0.00224	CcSEcCtD
Methyclothiazide—Body temperature increased—Sunitinib—kidney cancer	0.000295	0.00224	CcSEcCtD
Methyclothiazide—Diarrhoea—Erlotinib—kidney cancer	0.000295	0.00224	CcSEcCtD
Methyclothiazide—Thrombocytopenia—Gemcitabine—kidney cancer	0.000294	0.00222	CcSEcCtD
Methyclothiazide—Vision blurred—Paclitaxel—kidney cancer	0.00029	0.00219	CcSEcCtD
Methyclothiazide—Hypersensitivity—Sorafenib—kidney cancer	0.000286	0.00217	CcSEcCtD
Methyclothiazide—Anorexia—Gemcitabine—kidney cancer	0.000286	0.00216	CcSEcCtD
Methyclothiazide—Vomiting—Vinblastine—kidney cancer	0.000286	0.00216	CcSEcCtD
Methyclothiazide—Dizziness—Erlotinib—kidney cancer	0.000285	0.00216	CcSEcCtD
Methyclothiazide—Vomiting—Everolimus—kidney cancer	0.000284	0.00215	CcSEcCtD
Methyclothiazide—Paraesthesia—Vincristine—kidney cancer	0.000284	0.00215	CcSEcCtD
Methyclothiazide—Agitation—Paclitaxel—kidney cancer	0.000283	0.00214	CcSEcCtD
Methyclothiazide—Rash—Everolimus—kidney cancer	0.000282	0.00213	CcSEcCtD
Methyclothiazide—Dermatitis—Everolimus—kidney cancer	0.000282	0.00213	CcSEcCtD
Methyclothiazide—Headache—Vinblastine—kidney cancer	0.000281	0.00213	CcSEcCtD
Methyclothiazide—Purpura—Doxorubicin—kidney cancer	0.00028	0.00212	CcSEcCtD
Methyclothiazide—Headache—Everolimus—kidney cancer	0.00028	0.00212	CcSEcCtD
Methyclothiazide—Body temperature increased—Dactinomycin—kidney cancer	0.00028	0.00212	CcSEcCtD
Methyclothiazide—Asthenia—Sorafenib—kidney cancer	0.000279	0.00211	CcSEcCtD
Methyclothiazide—Vertigo—Paclitaxel—kidney cancer	0.000276	0.00209	CcSEcCtD
Methyclothiazide—Leukopenia—Paclitaxel—kidney cancer	0.000275	0.00208	CcSEcCtD
Methyclothiazide—Hypersensitivity—Sunitinib—kidney cancer	0.000275	0.00208	CcSEcCtD
Methyclothiazide—Decreased appetite—Vincristine—kidney cancer	0.000275	0.00208	CcSEcCtD
Methyclothiazide—Vomiting—Erlotinib—kidney cancer	0.000274	0.00208	CcSEcCtD
Methyclothiazide—Erythema multiforme—Capecitabine—kidney cancer	0.000274	0.00208	CcSEcCtD
Methyclothiazide—Rash—Erlotinib—kidney cancer	0.000272	0.00206	CcSEcCtD
Methyclothiazide—Dermatitis—Erlotinib—kidney cancer	0.000272	0.00206	CcSEcCtD
Methyclothiazide—Headache—Erlotinib—kidney cancer	0.00027	0.00205	CcSEcCtD
Methyclothiazide—Constipation—Vincristine—kidney cancer	0.00027	0.00205	CcSEcCtD
Methyclothiazide—Paraesthesia—Gemcitabine—kidney cancer	0.000269	0.00204	CcSEcCtD
Methyclothiazide—Asthenia—Sunitinib—kidney cancer	0.000268	0.00203	CcSEcCtD
Methyclothiazide—SLC12A1—SLC-mediated transmembrane transport—SLC5A5—kidney cancer	0.000268	0.00532	CbGpPWpGaD
Methyclothiazide—Nausea—Vinblastine—kidney cancer	0.000267	0.00202	CcSEcCtD
Methyclothiazide—Nausea—Everolimus—kidney cancer	0.000266	0.00201	CcSEcCtD
Methyclothiazide—Diarrhoea—Sorafenib—kidney cancer	0.000266	0.00201	CcSEcCtD
Methyclothiazide—CA1—C-MYB transcription factor network—KIT—kidney cancer	0.000262	0.0052	CbGpPWpGaD
Methyclothiazide—Decreased appetite—Gemcitabine—kidney cancer	0.000261	0.00197	CcSEcCtD
Methyclothiazide—Hypersensitivity—Dactinomycin—kidney cancer	0.000261	0.00197	CcSEcCtD
Methyclothiazide—SLC12A1—SLC-mediated transmembrane transport—SLC2A1—kidney cancer	0.000258	0.00514	CbGpPWpGaD
Methyclothiazide—SLC12A1—Transmembrane transport of small molecules—SLC5A3—kidney cancer	0.000258	0.00513	CbGpPWpGaD
Methyclothiazide—SLC12A1—Transmembrane transport of small molecules—ANXA2—kidney cancer	0.000258	0.00513	CbGpPWpGaD
Methyclothiazide—SLC12A1—Transmembrane transport of small molecules—ATP7B—kidney cancer	0.000258	0.00513	CbGpPWpGaD
Methyclothiazide—Dizziness—Sorafenib—kidney cancer	0.000257	0.00194	CcSEcCtD
Methyclothiazide—Constipation—Gemcitabine—kidney cancer	0.000256	0.00194	CcSEcCtD
Methyclothiazide—Nausea—Erlotinib—kidney cancer	0.000256	0.00194	CcSEcCtD
Methyclothiazide—Diarrhoea—Sunitinib—kidney cancer	0.000256	0.00194	CcSEcCtD
Methyclothiazide—Asthenia—Dactinomycin—kidney cancer	0.000254	0.00192	CcSEcCtD
Methyclothiazide—Malnutrition—Capecitabine—kidney cancer	0.000252	0.00191	CcSEcCtD
Methyclothiazide—Anaphylactic shock—Paclitaxel—kidney cancer	0.000251	0.0019	CcSEcCtD
Methyclothiazide—Body temperature increased—Vincristine—kidney cancer	0.00025	0.00189	CcSEcCtD
Methyclothiazide—Dizziness—Sunitinib—kidney cancer	0.000247	0.00187	CcSEcCtD
Methyclothiazide—Vomiting—Sorafenib—kidney cancer	0.000247	0.00187	CcSEcCtD
Methyclothiazide—Orthostatic hypotension—Doxorubicin—kidney cancer	0.000247	0.00187	CcSEcCtD
Methyclothiazide—Thrombocytopenia—Paclitaxel—kidney cancer	0.000246	0.00186	CcSEcCtD
Methyclothiazide—Rash—Sorafenib—kidney cancer	0.000245	0.00185	CcSEcCtD
Methyclothiazide—Dermatitis—Sorafenib—kidney cancer	0.000245	0.00185	CcSEcCtD
Methyclothiazide—Headache—Sorafenib—kidney cancer	0.000243	0.00184	CcSEcCtD
Methyclothiazide—SLC12A3—SLC-mediated transmembrane transport—SLC5A5—kidney cancer	0.000243	0.00483	CbGpPWpGaD
Methyclothiazide—Muscle spasms—Capecitabine—kidney cancer	0.000243	0.00184	CcSEcCtD
Methyclothiazide—Diarrhoea—Dactinomycin—kidney cancer	0.000242	0.00183	CcSEcCtD
Methyclothiazide—Anorexia—Paclitaxel—kidney cancer	0.000239	0.00181	CcSEcCtD
Methyclothiazide—Vision blurred—Capecitabine—kidney cancer	0.000238	0.0018	CcSEcCtD
Methyclothiazide—Vomiting—Sunitinib—kidney cancer	0.000238	0.0018	CcSEcCtD
Methyclothiazide—Body temperature increased—Gemcitabine—kidney cancer	0.000237	0.00179	CcSEcCtD
Methyclothiazide—Rash—Sunitinib—kidney cancer	0.000236	0.00178	CcSEcCtD
Methyclothiazide—Dermatitis—Sunitinib—kidney cancer	0.000235	0.00178	CcSEcCtD
Methyclothiazide—SLC12A3—SLC-mediated transmembrane transport—SLC2A1—kidney cancer	0.000235	0.00466	CbGpPWpGaD
Methyclothiazide—SLC12A3—Transmembrane transport of small molecules—ATP7B—kidney cancer	0.000234	0.00465	CbGpPWpGaD
Methyclothiazide—SLC12A3—Transmembrane transport of small molecules—SLC5A3—kidney cancer	0.000234	0.00465	CbGpPWpGaD
Methyclothiazide—SLC12A3—Transmembrane transport of small molecules—ANXA2—kidney cancer	0.000234	0.00465	CbGpPWpGaD
Methyclothiazide—Headache—Sunitinib—kidney cancer	0.000234	0.00177	CcSEcCtD
Methyclothiazide—Hypersensitivity—Vincristine—kidney cancer	0.000233	0.00176	CcSEcCtD
Methyclothiazide—Nausea—Sorafenib—kidney cancer	0.000231	0.00175	CcSEcCtD
Methyclothiazide—Pancreatitis—Doxorubicin—kidney cancer	0.000229	0.00173	CcSEcCtD
Methyclothiazide—Vertigo—Capecitabine—kidney cancer	0.000227	0.00172	CcSEcCtD
Methyclothiazide—Asthenia—Vincristine—kidney cancer	0.000227	0.00172	CcSEcCtD
Methyclothiazide—Leukopenia—Capecitabine—kidney cancer	0.000226	0.00171	CcSEcCtD
Methyclothiazide—Paraesthesia—Paclitaxel—kidney cancer	0.000225	0.00171	CcSEcCtD
Methyclothiazide—Vomiting—Dactinomycin—kidney cancer	0.000225	0.0017	CcSEcCtD
Methyclothiazide—Rash—Dactinomycin—kidney cancer	0.000223	0.00169	CcSEcCtD
Methyclothiazide—Nausea—Sunitinib—kidney cancer	0.000222	0.00168	CcSEcCtD
Methyclothiazide—Decreased appetite—Paclitaxel—kidney cancer	0.000218	0.00165	CcSEcCtD
Methyclothiazide—Diarrhoea—Vincristine—kidney cancer	0.000216	0.00164	CcSEcCtD
Methyclothiazide—Asthenia—Gemcitabine—kidney cancer	0.000215	0.00163	CcSEcCtD
Methyclothiazide—Constipation—Paclitaxel—kidney cancer	0.000215	0.00162	CcSEcCtD
Methyclothiazide—Photosensitivity reaction—Doxorubicin—kidney cancer	0.000213	0.00161	CcSEcCtD
Methyclothiazide—CA1—C-MYB transcription factor network—CDKN2A—kidney cancer	0.000212	0.00422	CbGpPWpGaD
Methyclothiazide—Hyperglycaemia—Doxorubicin—kidney cancer	0.000211	0.00159	CcSEcCtD
Methyclothiazide—Nausea—Dactinomycin—kidney cancer	0.00021	0.00159	CcSEcCtD
Methyclothiazide—Pneumonia—Doxorubicin—kidney cancer	0.000209	0.00158	CcSEcCtD
Methyclothiazide—Dizziness—Vincristine—kidney cancer	0.000209	0.00158	CcSEcCtD
Methyclothiazide—Stevens-Johnson syndrome—Doxorubicin—kidney cancer	0.000206	0.00156	CcSEcCtD
Methyclothiazide—Diarrhoea—Gemcitabine—kidney cancer	0.000205	0.00155	CcSEcCtD
Methyclothiazide—Jaundice—Doxorubicin—kidney cancer	0.000203	0.00154	CcSEcCtD
Methyclothiazide—Thrombocytopenia—Capecitabine—kidney cancer	0.000202	0.00153	CcSEcCtD
Methyclothiazide—Vomiting—Vincristine—kidney cancer	0.000201	0.00152	CcSEcCtD
Methyclothiazide—CA1—C-MYB transcription factor network—CD4—kidney cancer	0.0002	0.00398	CbGpPWpGaD
Methyclothiazide—Urticaria—Paclitaxel—kidney cancer	0.000199	0.00151	CcSEcCtD
Methyclothiazide—Rash—Vincristine—kidney cancer	0.000199	0.00151	CcSEcCtD
Methyclothiazide—Dermatitis—Vincristine—kidney cancer	0.000199	0.00151	CcSEcCtD
Methyclothiazide—CA1—C-MYB transcription factor network—PTGS2—kidney cancer	0.000199	0.00395	CbGpPWpGaD
Methyclothiazide—Body temperature increased—Paclitaxel—kidney cancer	0.000198	0.0015	CcSEcCtD
Methyclothiazide—Headache—Vincristine—kidney cancer	0.000198	0.0015	CcSEcCtD
Methyclothiazide—Anorexia—Capecitabine—kidney cancer	0.000196	0.00149	CcSEcCtD
Methyclothiazide—Agranulocytosis—Doxorubicin—kidney cancer	0.000194	0.00147	CcSEcCtD
Methyclothiazide—Vomiting—Gemcitabine—kidney cancer	0.000191	0.00144	CcSEcCtD
Methyclothiazide—Rash—Gemcitabine—kidney cancer	0.000189	0.00143	CcSEcCtD
Methyclothiazide—Dermatitis—Gemcitabine—kidney cancer	0.000189	0.00143	CcSEcCtD
Methyclothiazide—CA1—C-MYB transcription factor network—CDKN1B—kidney cancer	0.000188	0.00374	CbGpPWpGaD
Methyclothiazide—Headache—Gemcitabine—kidney cancer	0.000188	0.00142	CcSEcCtD
Methyclothiazide—Nausea—Vincristine—kidney cancer	0.000188	0.00142	CcSEcCtD
Methyclothiazide—Paraesthesia—Capecitabine—kidney cancer	0.000185	0.0014	CcSEcCtD
Methyclothiazide—Hypersensitivity—Paclitaxel—kidney cancer	0.000185	0.0014	CcSEcCtD
Methyclothiazide—Asthenia—Paclitaxel—kidney cancer	0.00018	0.00136	CcSEcCtD
Methyclothiazide—CA4—Metabolism—ACY1—kidney cancer	0.00018	0.00358	CbGpPWpGaD
Methyclothiazide—CA1—C-MYB transcription factor network—CCND1—kidney cancer	0.000179	0.00357	CbGpPWpGaD
Methyclothiazide—Decreased appetite—Capecitabine—kidney cancer	0.000179	0.00136	CcSEcCtD
Methyclothiazide—Nausea—Gemcitabine—kidney cancer	0.000178	0.00135	CcSEcCtD
Methyclothiazide—Erythema multiforme—Doxorubicin—kidney cancer	0.000177	0.00134	CcSEcCtD
Methyclothiazide—Constipation—Capecitabine—kidney cancer	0.000176	0.00133	CcSEcCtD
Methyclothiazide—CA2—Metabolism—ACY1—kidney cancer	0.000173	0.00343	CbGpPWpGaD
Methyclothiazide—Diarrhoea—Paclitaxel—kidney cancer	0.000172	0.0013	CcSEcCtD
Methyclothiazide—Dizziness—Paclitaxel—kidney cancer	0.000166	0.00126	CcSEcCtD
Methyclothiazide—CA1—Metabolism—ACY1—kidney cancer	0.000166	0.00329	CbGpPWpGaD
Methyclothiazide—Urticaria—Capecitabine—kidney cancer	0.000164	0.00124	CcSEcCtD
Methyclothiazide—Body temperature increased—Capecitabine—kidney cancer	0.000163	0.00123	CcSEcCtD
Methyclothiazide—Malnutrition—Doxorubicin—kidney cancer	0.000163	0.00123	CcSEcCtD
Methyclothiazide—Vomiting—Paclitaxel—kidney cancer	0.00016	0.00121	CcSEcCtD
Methyclothiazide—Rash—Paclitaxel—kidney cancer	0.000158	0.0012	CcSEcCtD
Methyclothiazide—Dermatitis—Paclitaxel—kidney cancer	0.000158	0.0012	CcSEcCtD
Methyclothiazide—Headache—Paclitaxel—kidney cancer	0.000157	0.00119	CcSEcCtD
Methyclothiazide—Muscle spasms—Doxorubicin—kidney cancer	0.000156	0.00118	CcSEcCtD
Methyclothiazide—Vision blurred—Doxorubicin—kidney cancer	0.000153	0.00116	CcSEcCtD
Methyclothiazide—CA4—Metabolism—PDHB—kidney cancer	0.000153	0.00304	CbGpPWpGaD
Methyclothiazide—Hypersensitivity—Capecitabine—kidney cancer	0.000152	0.00115	CcSEcCtD
Methyclothiazide—Agitation—Doxorubicin—kidney cancer	0.00015	0.00113	CcSEcCtD
Methyclothiazide—Nausea—Paclitaxel—kidney cancer	0.000149	0.00113	CcSEcCtD
Methyclothiazide—Asthenia—Capecitabine—kidney cancer	0.000148	0.00112	CcSEcCtD
Methyclothiazide—CA2—Metabolism—PDHB—kidney cancer	0.000147	0.00292	CbGpPWpGaD
Methyclothiazide—Vertigo—Doxorubicin—kidney cancer	0.000146	0.00111	CcSEcCtD
Methyclothiazide—Leukopenia—Doxorubicin—kidney cancer	0.000146	0.0011	CcSEcCtD
Methyclothiazide—CA4—Metabolism—CCBL1—kidney cancer	0.000144	0.00286	CbGpPWpGaD
Methyclothiazide—CA1—C-MYB transcription factor network—MYC—kidney cancer	0.000144	0.00286	CbGpPWpGaD
Methyclothiazide—Diarrhoea—Capecitabine—kidney cancer	0.000141	0.00107	CcSEcCtD
Methyclothiazide—CA1—Metabolism—PDHB—kidney cancer	0.000141	0.0028	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—CCBL1—kidney cancer	0.000138	0.00274	CbGpPWpGaD
Methyclothiazide—Dizziness—Capecitabine—kidney cancer	0.000136	0.00103	CcSEcCtD
Methyclothiazide—SLC12A1—Transmembrane transport of small molecules—SLC5A5—kidney cancer	0.000136	0.0027	CbGpPWpGaD
Methyclothiazide—CA1—C-MYB transcription factor network—KRAS—kidney cancer	0.000133	0.00264	CbGpPWpGaD
Methyclothiazide—Anaphylactic shock—Doxorubicin—kidney cancer	0.000133	0.00101	CcSEcCtD
Methyclothiazide—CA1—Metabolism—CCBL1—kidney cancer	0.000132	0.00263	CbGpPWpGaD
Methyclothiazide—SLC12A1—Transmembrane transport of small molecules—SLC2A1—kidney cancer	0.000131	0.00261	CbGpPWpGaD
Methyclothiazide—Vomiting—Capecitabine—kidney cancer	0.000131	0.000991	CcSEcCtD
Methyclothiazide—Thrombocytopenia—Doxorubicin—kidney cancer	0.00013	0.000984	CcSEcCtD
Methyclothiazide—Rash—Capecitabine—kidney cancer	0.00013	0.000983	CcSEcCtD
Methyclothiazide—Dermatitis—Capecitabine—kidney cancer	0.00013	0.000982	CcSEcCtD
Methyclothiazide—Headache—Capecitabine—kidney cancer	0.000129	0.000977	CcSEcCtD
Methyclothiazide—Anorexia—Doxorubicin—kidney cancer	0.000127	0.000958	CcSEcCtD
Methyclothiazide—CA4—Metabolism—PPAT—kidney cancer	0.000125	0.00248	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—GLIPR1—kidney cancer	0.000125	0.00248	CbGpPWpGaD
Methyclothiazide—SLC12A3—Transmembrane transport of small molecules—SLC5A5—kidney cancer	0.000123	0.00245	CbGpPWpGaD
Methyclothiazide—Nausea—Capecitabine—kidney cancer	0.000122	0.000926	CcSEcCtD
Methyclothiazide—CA2—Metabolism—PPAT—kidney cancer	0.00012	0.00238	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—GLIPR1—kidney cancer	0.00012	0.00238	CbGpPWpGaD
Methyclothiazide—SLC12A3—Transmembrane transport of small molecules—SLC2A1—kidney cancer	0.000119	0.00237	CbGpPWpGaD
Methyclothiazide—Paraesthesia—Doxorubicin—kidney cancer	0.000119	0.000902	CcSEcCtD
Methyclothiazide—CA4—Metabolism—APRT—kidney cancer	0.000116	0.00231	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—FH—kidney cancer	0.000116	0.00231	CbGpPWpGaD
Methyclothiazide—Decreased appetite—Doxorubicin—kidney cancer	0.000115	0.000874	CcSEcCtD
Methyclothiazide—CA1—Metabolism—GLIPR1—kidney cancer	0.000115	0.00228	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—PPAT—kidney cancer	0.000115	0.00228	CbGpPWpGaD
Methyclothiazide—Constipation—Doxorubicin—kidney cancer	0.000114	0.000859	CcSEcCtD
Methyclothiazide—CA2—Metabolism—FH—kidney cancer	0.000111	0.00221	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—APRT—kidney cancer	0.000111	0.00221	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—GPC3—kidney cancer	0.000109	0.00217	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—FH—kidney cancer	0.000107	0.00212	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—APRT—kidney cancer	0.000107	0.00212	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—CA2—kidney cancer	0.000106	0.00211	CbGpPWpGaD
Methyclothiazide—Urticaria—Doxorubicin—kidney cancer	0.000105	0.000798	CcSEcCtD
Methyclothiazide—Body temperature increased—Doxorubicin—kidney cancer	0.000105	0.000795	CcSEcCtD
Methyclothiazide—CA2—Metabolism—GPC3—kidney cancer	0.000105	0.00208	CbGpPWpGaD
Methyclothiazide—SLC12A1—Transmembrane transport of small molecules—ABCB1—kidney cancer	0.000104	0.00206	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—ALAD—kidney cancer	0.000103	0.00206	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—ST3GAL2—kidney cancer	0.000101	0.00201	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—GPC3—kidney cancer	0.0001	0.00199	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—ALAD—kidney cancer	9.92e-05	0.00197	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—ALDH1A1—kidney cancer	9.87e-05	0.00196	CbGpPWpGaD
Methyclothiazide—Hypersensitivity—Doxorubicin—kidney cancer	9.78e-05	0.00074	CcSEcCtD
Methyclothiazide—CA1—Metabolism—CA2—kidney cancer	9.76e-05	0.00194	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—ST3GAL2—kidney cancer	9.68e-05	0.00192	CbGpPWpGaD
Methyclothiazide—Asthenia—Doxorubicin—kidney cancer	9.53e-05	0.000721	CcSEcCtD
Methyclothiazide—CA1—Metabolism—ALAD—kidney cancer	9.51e-05	0.00189	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—ALDH1A1—kidney cancer	9.46e-05	0.00188	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—SLC5A3—kidney cancer	9.46e-05	0.00188	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—PGK1—kidney cancer	9.46e-05	0.00188	CbGpPWpGaD
Methyclothiazide—SLC12A3—Transmembrane transport of small molecules—ABCB1—kidney cancer	9.42e-05	0.00187	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—ST3GAL2—kidney cancer	9.28e-05	0.00184	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—LDHB—kidney cancer	9.28e-05	0.00184	CbGpPWpGaD
Methyclothiazide—Diarrhoea—Doxorubicin—kidney cancer	9.09e-05	0.000688	CcSEcCtD
Methyclothiazide—CA1—Metabolism—ALDH1A1—kidney cancer	9.07e-05	0.0018	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—SLC5A3—kidney cancer	9.07e-05	0.0018	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—PGK1—kidney cancer	9.07e-05	0.0018	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—LDHB—kidney cancer	8.9e-05	0.00177	CbGpPWpGaD
Methyclothiazide—Dizziness—Doxorubicin—kidney cancer	8.78e-05	0.000665	CcSEcCtD
Methyclothiazide—CA1—Metabolism—PGK1—kidney cancer	8.7e-05	0.00173	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—SLC5A3—kidney cancer	8.7e-05	0.00173	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—LDHB—kidney cancer	8.53e-05	0.0017	CbGpPWpGaD
Methyclothiazide—Vomiting—Doxorubicin—kidney cancer	8.44e-05	0.000639	CcSEcCtD
Methyclothiazide—Rash—Doxorubicin—kidney cancer	8.37e-05	0.000634	CcSEcCtD
Methyclothiazide—Dermatitis—Doxorubicin—kidney cancer	8.37e-05	0.000633	CcSEcCtD
Methyclothiazide—Headache—Doxorubicin—kidney cancer	8.32e-05	0.00063	CcSEcCtD
Methyclothiazide—CA4—Metabolism—CA9—kidney cancer	8.04e-05	0.0016	CbGpPWpGaD
Methyclothiazide—Nausea—Doxorubicin—kidney cancer	7.89e-05	0.000597	CcSEcCtD
Methyclothiazide—CA2—Metabolism—CA9—kidney cancer	7.71e-05	0.00153	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—CA9—kidney cancer	7.39e-05	0.00147	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—CRABP1—kidney cancer	6.84e-05	0.00136	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—CRABP1—kidney cancer	6.56e-05	0.0013	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—ITPR2—kidney cancer	6.36e-05	0.00126	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—CRABP1—kidney cancer	6.29e-05	0.00125	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—ITPR2—kidney cancer	6.1e-05	0.00121	CbGpPWpGaD
Methyclothiazide—SLC12A1—Transmembrane transport of small molecules—RAF1—kidney cancer	5.87e-05	0.00117	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—ITPR2—kidney cancer	5.85e-05	0.00116	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—GSTT1—kidney cancer	5.8e-05	0.00115	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—ACHE—kidney cancer	5.8e-05	0.00115	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—ACHE—kidney cancer	5.56e-05	0.00111	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—GSTT1—kidney cancer	5.56e-05	0.00111	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—SCARB1—kidney cancer	5.49e-05	0.00109	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—PTGS1—kidney cancer	5.43e-05	0.00108	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—GSTT1—kidney cancer	5.33e-05	0.00106	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—ACHE—kidney cancer	5.33e-05	0.00106	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—PSMD7—kidney cancer	5.33e-05	0.00106	CbGpPWpGaD
Methyclothiazide—SLC12A3—Transmembrane transport of small molecules—RAF1—kidney cancer	5.33e-05	0.00106	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—SCARB1—kidney cancer	5.26e-05	0.00105	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—PTGS1—kidney cancer	5.21e-05	0.00104	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—PSMD7—kidney cancer	5.11e-05	0.00102	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—BCHE—kidney cancer	5.05e-05	0.001	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—SCARB1—kidney cancer	5.05e-05	0.001	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—PTGS1—kidney cancer	4.99e-05	0.000993	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—SLC5A5—kidney cancer	4.99e-05	0.000992	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—PSMD7—kidney cancer	4.9e-05	0.000974	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—BCHE—kidney cancer	4.84e-05	0.000963	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—SLC2A1—kidney cancer	4.82e-05	0.000958	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—SLC5A5—kidney cancer	4.78e-05	0.000951	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—BCHE—kidney cancer	4.64e-05	0.000923	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—SLC2A1—kidney cancer	4.62e-05	0.000918	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—SLC5A5—kidney cancer	4.59e-05	0.000912	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—SLC2A1—kidney cancer	4.43e-05	0.00088	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—GSTP1—kidney cancer	4.02e-05	0.000799	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—GSTP1—kidney cancer	3.85e-05	0.000766	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—ABCB1—kidney cancer	3.8e-05	0.000756	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—GSTP1—kidney cancer	3.69e-05	0.000734	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—GSTM1—kidney cancer	3.69e-05	0.000734	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—ABCB1—kidney cancer	3.65e-05	0.000725	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—GSTM1—kidney cancer	3.54e-05	0.000704	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—CYP1A1—kidney cancer	3.5e-05	0.000696	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—ABCB1—kidney cancer	3.5e-05	0.000695	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—GSTM1—kidney cancer	3.4e-05	0.000675	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—CYP1A1—kidney cancer	3.36e-05	0.000667	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—CYP1A1—kidney cancer	3.22e-05	0.00064	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—POMC—kidney cancer	2.61e-05	0.000519	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—POMC—kidney cancer	2.5e-05	0.000497	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—POMC—kidney cancer	2.4e-05	0.000477	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—PTGS2—kidney cancer	2.08e-05	0.000414	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—PTGS2—kidney cancer	2e-05	0.000397	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—PTGS2—kidney cancer	1.91e-05	0.00038	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—PTEN—kidney cancer	1.82e-05	0.000361	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—PTEN—kidney cancer	1.74e-05	0.000346	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—PTEN—kidney cancer	1.67e-05	0.000332	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—PIK3CA—kidney cancer	1.28e-05	0.000255	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—PIK3CA—kidney cancer	1.23e-05	0.000244	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—PIK3CA—kidney cancer	1.18e-05	0.000234	CbGpPWpGaD
